Medpace (MEDP) Stock Price, News & Analysis

Company Overview

Medpace Holdings, Inc. is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services. The company also provides specialized support for areas such as imaging, bioanalytical testing and clinical trial logistics. Its work spans multiple therapeutic areas, including oncology, cardiology, central nervous system disorders, metabolic disease, infectious disease and medical devices.

Headquartered in Cincinnati, Ohio, Medpace conducts and supports studies through operations serving North America, Europe, Asia-Pacific and other international markets. The company was founded in 1992 by August J. Troendle, who serves as its chairman and chief executive officer. Medpace Holdings became a publicly traded company on the Nasdaq under the symbol MEDP in 2016.

Key Stats

• Today's Range: $645.93 to $670.18
• 50-Day Range: $583.16 to $669.20
• 52-Week Range: $373.00 to $684.52
• Volume: 309,423 shs
• Average Volume: 332,400 shs
• Market Capitalization: $18.68 billion
• P/E Ratio: 37.10
• Dividend Yield: N/A
• Price Target: $642.91
• Consensus Rating: Hold

Medpace Stock Analysis - MarketRank™

Medpace scored higher than 59% of companies evaluated by MarketBeat, and ranked 504th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Medpace has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on no strong buy ratings, 3 buy ratings, 10 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Medpace is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Medpace has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 8.14%

Earnings Growth

Earnings for Medpace are expected to grow by 8.14% in the coming year, from $18.06 to $19.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medpace is 37.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medpace is 37.10, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.89.

Price to Earnings Growth Ratio

Medpace has a PEG Ratio of 2.97. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Medpace has a P/B Ratio of 31.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.19% of the float of Medpace has been sold short.

Short Interest Ratio / Days to Cover

Medpace has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Medpace has recently decreased by 5.30%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medpace does not currently pay a dividend.

Dividend Growth

Medpace does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.44

News Sentiment

Medpace has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 34 news articles for Medpace this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for MEDP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

8 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Medpace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,008,328.00 in company stock.

Percentage Held by Insiders

20.50% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/21/2026
• Today: 10/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:MEDP
• CIK: 1668397
• Web: www.medpace.com
• Phone: (513) 579-9911
• Fax: 513-579-0444
• Employees: 6,200
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Medpace: $642.91
• High Price Target: $730.00
• Low Price Target: $515.00
• Potential Upside/Downside: -3.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.23
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): $18.04
• Trailing P/E Ratio: 37.10
• Forward P/E Ratio: 37.05
• P/E Growth: 2.97
• Net Income: $451.12 million
• Net Margins: 18.24%
• Pretax Margin: 22.09%
• Return on Equity: 99.76%
• Return on Assets: 24.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.83
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $2.53 billion
• Price / Sales: 7.38
• Cash Flow: $17.02 per share
• Price / Cash Flow: 39.33
• Book Value: $20.96 per share
• Price / Book: 31.93

Miscellaneous

• Outstanding Shares: 27,910,000
• Free Float: 22,190,000
• Market Cap: $18.68 billion
• Optionable: Optionable
• Beta: 1.18